Xilio Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biotechnology company based in the United States, with headquarters in Waltham, Massachusetts. For European investors, Xilio is best understood as a small-cap U.S. biotech focused on next-generation immuno-oncology, specifically masked or tumor-activated therapies designed to improve the therapeutic window of cancer treatments. The company was built around a proprietary masking platform intended to keep drug activity concentrated in the tumor microenvironment, thereby reducing systemic exposure and potentially improving tolerability. Xilio trades on the NASDAQ market in the United States, which places it squarely in the group of U.S. biotech names that are typically driven by clinical catalysts, partnership updates, and financing needs. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-pipeline-and-business-updates-11/?utm_source=openai)) Xilio’s business model combines internal drug development with collaboration and licensing agreements that can generate milestone payments and other non-dilutive funding. The company’s core strategic asset is its clinically validated masking technology, which it uses to design immuno-oncology therapies with the goal of achieving stronger tumor selectivity than conventional approaches. Its current pipeline includes XTX501, a masked bispecific PD-1 / IL-2 program that management has described as a potential backbone therapy for combination regimens across solid tumors, as well as XTX601, a masked T-cell engager targeting CLDN18.2. Xilio is also advancing additional masked programs, giving it a platform story rather than dependence on a single asset. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-reports-first-quarter-2026-financial-results?utm_source=openai)) Competitively, Xilio occupies an attractive but highly risky niche. Its potential edge lies in its ability to mask active agents until they reach the tumor, which could matter in solid tumors where toxicity has historically limited the utility of cytokines and T-cell engagers. At the same time, the company competes with larger biopharma groups and better-capitalized biotech peers pursuing bispecific antibodies, engineered cytokines, and T-cell engager platforms. Xilio’s valuation therefore depends heavily on early clinical validation, IND-enabling progress, regulatory execution, and the ability to secure collaborations or additional capital. Like many clinical-stage biotech companies, it does not yet have a commercial product base, so the investment case is still primarily binary and event-driven. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-pipeline-and-business-updates-11/?utm_source=openai)) Recent highlights include first-quarter 2026 financial results, new preclinical data presented at AACR 2026 for XTX601, and continued advancement of XTX501 toward an expected IND submission in 2026. The company also reported pipeline and business updates in early 2026 and had previously closed a $50 million public offering in 2025 to support development and general corporate purposes. Overall, Xilio remains a high-risk, high-catalyst U.S. biotech story: scientifically differentiated, still pre-commercial, and highly dependent on execution milestones over the next several quarters. ([ir.xiliotx.com](https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-reports-first-quarter-2026-financial-results?utm_source=openai))